Evolent Health, Inc.
EVH
$9.55
$0.010.11%
| Weiss Ratings | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.88 | |||
| Price History | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 9.27% | |||
| 30-Day Total Return | -9.74% | |||
| 60-Day Total Return | -16.08% | |||
| 90-Day Total Return | -59.10% | |||
| Year to Date Total Return | -16.88% | |||
| 1-Year Total Return | -71.48% | |||
| 2-Year Total Return | -69.00% | |||
| 3-Year Total Return | -65.70% | |||
| 5-Year Total Return | 162.36% | |||
| 52-Week High % Change | -71.78% | |||
| 52-Week Low % Change | 14.25% | |||
| Price | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $33.80 | |||
| 52-Week Low Price | $8.35 | |||
| 52-Week Low Price (Date) | Mar 05, 2025 | |||
| 52-Week High Price (Date) | Mar 14, 2024 | |||
| Valuation | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.10B | |||
| Enterprise Value | 1.90B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.81 | |||
| Earnings Per Share Growth | -36.14% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.43 | |||
| Price/Book (Q) | 1.10 | |||
| Enterprise Value/Revenue (TTM) | 0.74 | |||
| Price | $9.55 | |||
| Enterprise Value/EBITDA (TTM) | 16.67 | |||
| Enterprise Value/EBIT | -1,387.90 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 115.03M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -32.59% | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 571 389 6000 | |||
| Address | 1812 N. Moore Street Arlington, VA 22209 | |||
| Website | www.evolent.com | |||
| Country | United States | |||
| Year Founded | 2011 | |||
| Profitability | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -0.05% | |||
| Profit Margin | -2.41% | |||
| Management Effectiveness | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -0.03% | |||
| Return on Equity | -- | |||
| Income Statement | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 2.55B | |||
| Total Revenue (TTM) | 2.55B | |||
| Revenue Per Share | $22.21 | |||
| Gross Profit (TTM) | 367.35M | |||
| EBITDA (TTM) | 113.81M | |||
| EBIT (TTM) | -1.37M | |||
| Net Income (TTM) | -61.62M | |||
| Net Income Avl. to Common (TTM) | -81.71M | |||
| Total Revenue Growth (Q YOY) | 16.27% | |||
| Earnings Growth (Q YOY) | 31.75% | |||
| EPS Diluted (TTM) | -0.81 | |||
| EPS Diluted Growth (Q YOY) | 26.98% | |||
| Balance Sheet | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 104.20M | |||
| Cash Per Share (Q) | $0.91 | |||
| Total Current Assets (Q) | 607.12M | |||
| Total Preferred Equity (Q) | 190.17 | |||
| Total Equity (Q) | 1.19B | |||
| Current Ratio (Q) | 0.849 | |||
| Book Value Per Share (Q) | $8.70 | |||
| Total Assets (Q) | 2.54B | |||
| Total Current Liabilities (Q) | 715.50M | |||
| Total Debt (Q) | 713.67M | |||
| Total Liabilities (Q) | 1.35B | |||
| Total Common Equity (Q) | 1.00B | |||
| Cash Flow | EVH - NYSE | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -62.93M | |||
| Cash from Financing (TTM) | -565.00K | |||
| Net Change in Cash (TTM) | -44.96M | |||
| Levered Free Cash Flow (TTM) | -42.22M | |||
| Cash from Operations (TTM) | 18.77M | |||
